ARWR vs RNA
ARWR: Arrowhead Pharmaceuticals is a clinical-stage biotechnology company leveraging its proprietary RNA interference (RNAi) platform to develop potent medicines that silence disease-causing genes. RNA: Atrium Therapeutics is pioneering precision RNA-based therapies to treat genetically driven cardiomyopathies by targeting disease drivers directly in the heart.
Side-by-side fundamentals
| Metric | ARWR | RNA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $60.74 | $8.26 | |
| Market cap | $8.6B | $141M | |
| Net margin FY2025, SEC XBRL | -0.2% | n/a | |
| Operating margin FY2025, SEC XBRL | +11.9% | n/a | |
| ROE FY2025, SEC XBRL | -0.3% | n/a | |
| ROA FY2025, SEC XBRL | -0.1% | n/a | |
| Debt / equity as of 2026-09-03 | 2.70 | 0.00 | RNA lower |
| Revenue growth (YoY) as of 2026-09-03 | +16.9% | +22.0% | RNA higher |
| Revenue CAGR (3y) SEC XBRL | +50.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.69 | 1.13 | |
| 1-year return as of 2026-10-08 close | +64.4% | -82.9% | ARWR higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.